




ophthalmology
futures forums 2025

EUROPEAN PROGRAMME

HOTEL D'ANGLETERRE
COPENHAGEN

Thurs. 11 Sept.



OFFICIAL GOLD SPONSOR OF OUR 2025 FORUMS



EUROPEAN FORUM 2025

Welcome

Welcome to Ophthalmology Futures 2025.

We are pleased to welcome you to our 14th Annual European Forum to be held for the second time in Copenhagen. Once again, this in-person event will bring together leading innovators, practitioners, corporate leaders and investors. We are delighted that over 30 companies will be presenting updates in their journeys to develop products to address unmet needs in vision threatening diseases. For the second consecutive year, we have had a record number of applications to present.

The company presentations are the highlight of every Ophthalmology Futures Forum, yet a unique additional characteristic of this meeting are the panel discussions that pose forthright questions to everyone in the innovation ecosystem. This year's panel topics will include discussions related to the impact of light adjustable IOL's, what is on the horizon with regard to advances in cataract and corneal surgery and myopia therapeutic study endpoints. We will explore the impact of novel lasers on existing minimally invasive

glaucoma surgical options and assess progress of breakthrough corneal therapies. As in prior years, we will hear from industry and investment leaders on the present and future health of the ophthalmology business.

Ophthalmology Futures Forums would like to thank our key advisors, corporate presenters and distinguished faculty for their invaluable support and assistance. We would also like to especially thank our sponsors who have provided support allowing us to keep registration costs low for all attendees!

Thank you for joining us in Copenhagen!

Keith Barton & Kuldev Singh

on behalf of the Ophthalmology Futures Team



ophthalmology
futures forums

Vision Futures Limited, London, UK.
Registered in England No: 8125858.



2026 FORUMS

Save the dates

RETINA FORUM

VIENNA

Weds. 30 Sept.

EUROPEAN FORUM

LONDON

Thurs. 10 Sept.



Keep up to date with the latest announcements
on our social channels

Help us make a difference

Your support helps create a
future without sight loss.

We can't do it without you.

moorfieldseyecharity.org.uk/support-us

We are the leading charity in the UK funding research into eye conditions like glaucoma and macular degeneration, and innovations in patient care to help patients worldwide. moorfieldseyecharity.org.uk

moorfields.eyecharity@nhs.net



Moorfields Eye Charity, 162 City Road, London EC1V 2PD
Telephone: [020 7566 2565](tel:02075662565)



Moorfields
Eye Charity

PROGRAMME COMMITTEE

>> Ike Ahmed

Division Head, Ophthalmology, Trilium Health Partners, Toronto, Canada. Assistant Professor, University of Toronto, Canada. Clinical Assistant Professor, University of Utah, USA.

>> Jorge Alio

Professor & Chairman of Ophthalmology, Miguel Hernandez University, Alicante, President, Visum Corporation, Spain.

>> Gerd Auffarth

Professor & Chairman, Dept. of Ophthalmology, University of Heidelberg. Director, David J. Apple International Laboratory for Ocular Pathology, International Vision Correction Research Centre, Heidelberg, Germany.

>> Francesco Bandello

Full Professor & Chairman Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele of Milan, Italy.

>> David Chang

Altos Eye Physicians & Clinical Professor, University of California, San Fran, USA.

>> Steve Charles

Founder & CEO, Charles Retina Institute. Clinical Professor of Ophthalmology, University of Tennessee, USA.

>> Paul Chew

Professor of Ophthalmology, National University of Singapore, Singapore.

>> Jost Jonas

Professor of Ophthalmology, Medical Faculty Mannheim, University of Heidelberg, Germany.

>> Sir Peng Khaw

Professor of Glaucoma & Ocular Healing, Director National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital & UCL Institute of Ophthalmology, London, UK.

>> Shigeru Kinoshita

Professor & Chair, Department of Ophthalmology, Kyoto Prefectural University of Medicine, Japan.

>> Richard Lindstrom

Founder & Attending Surgeon: Minnesota Eye Consultants, Minneapolis, USA. Adjunct Professor Emeritus: University of Minnesota, USA.

>> Ingeborg Stalmans

Head of the Glaucoma Clinic, University Hospitals UZ Leuven, Belgium. Head, Ophthalmology Research Group, University KU Leuven, Belgium.

>> Paulo Eduardo Stanga

Professor & Founder, The Retina Clinic London, UK.

>> José-Alain Sahel

Endowed Professor & Chairman, Department of Ophthalmology, University of Pittsburgh Medical Center, Pittsburgh, USA. Professor of Ophthalmology, Sorbonne Université. Chairman Departments of Ophthalmology, Quinze- Vingts National Ophthalmology Hospital & Rothschild Ophthalmology Foundation, Paris. Director, Institut de la Vision (Sorbonne Université, Inserm, CNRS, Paris).

>> Julian D. Stevens

Consultant Ophthalmic Surgeon, Moorfields Eye Hospital, London, UK.

>> Adnan Tufail

Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK. Professor, UCL Institute of Ophthalmology, London, UK.

>> Tien Yin Wong

Founding Head & Chair Professor, Tsinghua University, Beijing, China.

>> Ursula Schmidt-Erfurth

Professor & Chair, Medical University of Vienna, Austria.

>> ADVISORS

>> Laurent Attias

SVP, Head of Strategy, BD&L & Market Access, Alcon Inc., USA.

>> Eugene de Juan

Jean Kelly Stock Distinguished Chair, Ophthalmology, ForSight Labs & University of California, Menlo Park, California, USA.

>> Tom Dunlap

Founder, Dunlap Ophthalmology Consulting, Board of Directors, Advisory Boards.

>> Malvina Eydelman

CEO, Collaborative Community on Ophthalmic Innovation.

>> Reza Haque

SVP & Global Head of OIC, Ophthalmic Innovation Center, Santen Pharmaceutical.

>> Paul Hallen

VP & Global Head, Retina, Alcon, Texas, USA.

>> Jim Mazzo

Executive Chairman, Neurotech Pharmaceuticals.

>> Naveed Siddiqi

Novo Ventures.

>> ORGANISING COMMITTEE

>> Keith Barton

Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK, Professor of Ophthalmology, UCL, UK.

>> Kuldev Singh

Professor of Ophthalmology & Director, Glaucoma Service, Stanford University Medical Center, Palo Alto, USA.

>> Michael Sena

Operational Director, Ophthalmology Futures Forums, UK.

PREMIUM SPONSORS

>> PLATINUM



Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With an over 75-year heritage, we are the largest eye care device company in the world, with complementary businesses in Surgical and Vision Care. Being a truly global company, we work in 60 countries and serve patients in more than 140 countries. We have a long history of industry firsts, and each year we commit a substantial amount in Research and Development to meet customer needs and patient demands.

>> SILVER



BVI® is a diversified global ophthalmic device company with a mission to deliver high-quality solutions and innovation for advancing eye surgery and improving patients' vision. With nine decades of developing leading products and solutions, BVI partners with ophthalmic surgeons to improve the vision of

millions of patients across the globe. Our organization supports surgical teams in more than 90 countries worldwide, either directly or through our network of trusted distributors.

To learn more about BVI and its mission to advance the future of vision, visit www.bvimedical.com



EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. With over 200,000 employees across 150 countries, 650 operations facilities and 18,000 stores, in 2023 the Company generated consolidated revenue of Euro 25.4 billion. Its mission is to help people around the world to see more and be more by addressing their evolving vision needs and personal style aspirations. EssilorLuxottica is

home to the most advanced lens technologies including Varilux, Stellest and Transitions, the most iconic eyewear brands including Ray-Ban and Oakley, the most desired luxury licensed brands and world-class retailers including LensCrafters and Sunglass Hut. The Company's OneSight EssilorLuxottica Foundation has given access to sustainable vision care to more than 760 million people in underserved communities.

Thanks to the generosity of all of our sponsors, there is no fee for company presentations and virtual registration is complimentary for everyone.

>> GOLD



At Astellas, we are relentless in our pursuit of scientific progress and in identifying unmet medical needs by monitoring the changes in healthcare from multiple perspectives. We are committed to the realization of greater

VALUE by patients and healthcare systems around the world. We achieve this by leveraging our strengths to create innovative new drugs and to find solutions that drive patient access to healthcare and better outcomes.



STAAR Surgical (NASDAQ: STAA) is a global leader in implantable phakic intraocular lenses (ICLs), designed to reduce or eliminate the need for glasses or contacts. For over 30 years, STAAR has focused on developing and marketing its proprietary Implantable Collamer® Lenses, made from a biocompatible material proven to deliver long-term vision correction without removing

corneal tissue. The EVO ICL™ product line offers visual freedom through a quick, minimally invasive procedure. STAAR has sold over 3 million ICLs in 75+ countries. Founded in 1982 and headquartered in Lake Forest, California, STAAR also operates R&D, manufacturing, and packaging facilities in California and Switzerland.

Learn more at EVOICL.com and staar.com.



ZEISS Medical Technology: With a special focus on ophthalmology, ophthalmic surgery and visualization systems in the field of microsurgery, ZEISS Medical Technology supports healthcare professionals in setting new standards of care with proven medical technology

and broad application competence based on cutting-edge innovations.
www.zeiss.com

SPEAKERS

Panellists & Chairs

Presenting Companies

>> CHAIRS & PANEILLISTS

A

- **Sajjad Ahmad**
Professor of Corneal Regeneration, Moorfields Eye Hospital
- **Laurent Attias**
SVP, Corporate Strategy, BD&L & M&A, Alcon
- **Leon Au**
Consultant Ophthalmologist, Manchester Royal Eye Hospital
- **Gerd Auffarth**
Professor and Chairman, Heidelberg University Eye Hospital

B

- **Keith Barton**
Co-chair, Ophthalmology Futures Team
- **Ian Bell**
COO, Alcon
- **Antonio Boccardi**
VP Global Strategic Marketing, BVI Medical
- **Jan Bonel**
CEO & President, Lightfield Medical
- **Frank Bulens**
Partner, imec.xpand
- **Mark Bullimore**
Professor, University of Houston

C

- **Andrew Chang**
CCO, BVI Medical
- **David Chang**
Physician, Altos Eye Physicians
- **Arthur Cummings**
Ophthalmologist, Lightfield Medical

D

- **Annegret Dahlmann-Noor**
Consultant, Moorfields Eye Hospital
- **Sheraz Daya**
Consultant Ophthalmic Surgeon, Infinate Medical Ventures

- **Mor Dickman**
Professor, Head of Dept. of Ophthalmology, Uni of Utrecht
- **Kendall Donaldson**
Professor of Ophthalmology, Alcon

F

- **WARREN FOUST**
COO, Staar Surgical Company
- **Nahum Ferera**
CEO & Co-Founder, EyeYon Medical
- **Ian Flitcroft**
Founder & CIO, Ocumetra
- **Maximillian Foerst**
President & CEO, ZEISS

G

- **Damien Gatinel**
Head, Refractive & Cataract Surgery Dept., Fondation Ophtalmologique
- **Michael Giaquinto**
Managing Director, Wells Fargo

H

- **Yehia Hashad**
EVP, R&D & CMO, Bausch + Lomb
- **Kendra Hileman**
Head, Instrumentation R&D, Alcon
- **Cameron Hudson**
President, EU, Bausch + Lomb

J

- **Lionel Jouet**
VP, New Products Strategy & Global Marketing, Bausch + Lomb

K

- **Terry Kim**
VP, CMO & Medical Product Safety, Alcon
- **Shigeru Kinoshita**
Professor, Kyoto Prefectural University of Medicine
- **Mark Kontos**
Physician, Empire Eye Physicians

- **Shervin Korangy**
CEO, BVI Medical

L

- **Seba Leoni**
Global Head, Alcon Vision Suite, Alcon
- **Franck Leveiller**
CSO, SVP, Head Global R&D, Alcon
- **William Link**
Managing Partner, Versant Ventures
- **Richel Liu**
CEO, Rimongi Capital

M

- **Theresa Heah**
CEO, EYEXORA
- **Michael Goldstein**
President, CMO, Aurion Biotech
- **Riad Sherif, MD**
CEO, Oculis SA
- **Jim Mazzo**
Executive Chairman, Neurotech Pharmaceuticals
- **Cathleen McCabe**
Cataract Specialist, Bausch + Lomb
- **Jod Mehta**
Professor, Singapore National Eye Centre
- **Magda Michna**
Chief Clinical, Regulatory & Medical Affairs Officer, Staar Surgical Company
- **Michael Mrochen**
President, IROC Science AG

N


- **Manisha Narasimhan**
Chief Corporate Development & Digital Officer, Bausch + Lomb

O

- **Shawn O'Neil**
CCO, ViaLase, Inc.

P

- **Jai Parekh**
CCO / Co-Founder, Nordic Pharma



- **Ernesto Pelayo**
Director of Marketing – IOLs,
BVI Medical
- **Olga Prenat**
Head of Medical & Professional
Affairs, Essilor Luxottica

S

- **Enrica Sarnicola**
Ophthalmologist, Clinica degli
occhi Sarnicola
- **Steve Schallhorn**
CMO Ophthalmic Devices, ZEISS
- **Sunil Shah**
Director, Max Biotech Ltd.
- **Aimee Shimamoto**
VP Global Strategic Commercial
Marketing, BVI Medical
- **Kuldev Singh**
Co-chair, Ophthalmology Futures
Team
- **Katya Smirnyagina**
Senior Partner, Oxford Science
Enterprises
- **Ingeborg Stalmans**
Head of Glaucoma Clinic & Oph.
Research Group, KU Leuven

T

- **Vance Thompson**
MD, Vance Thompson Vision

V

- **Ramin Valian**
VP, Eye Care, Abbvie

Y

- **Ronald Yeoh**
Medical Director, Eye & Retina
Surgeons

Z

- **Roger Zaldivar**
CEO, REVAI
- **Dagny Zhu**
Medical Director & Partner,
NVISION Eye Centers



PRESENTING COMPANIES

#

- **2Eyes Vision**
Maximo Gomez, Strategic Operating
Partner

A

- **Allotex Inc.**
Michael Mrochen, President
- **Azalea Vision**
Enrique Vega, CEO

C

- **Ciliatech**
Olivier Benoît, Co-Founder & CEO

E

- **Epion Therapeutics Inc.**
Michael Webb, CEO
- **Eye Tech Care SA**
Dietrich Wolf, CEO
- **EyeYon Medical**
Nahum Ferera, Co-Founder & CEO

I

- **Infinite Medical Ventures**
Sheraz Daya, Consultant Ophthalmic
Surgeon
- **Intelon Optics**
Dimitri Chernyak, COO

L

- **Lightfield Medical**
Chip Berestka, Co-founder
- **Liqid Medical**
Daemon McClunan, Founder & CEO

M

- **machine MD**
Dominic Senn, CEO
- **Medevis Consulting**
Kristine Morrill, Founder & President

- **MICROT Inc.**
H. Joseph Yoon, MD, Director,
US Medical Affairs
- **Myra Vision Inc.**
Robert Chang, CEO

N

- **NovaSight Ltd.**
Ran Yam, CEO & Co-Founder

O

- **Ocumetra**
Ian Flitcroft, Founder & CIO
- **Occuity Ltd.**
Mark Jenkins, CCO
- **Ophthalmic Therapeutic
Innovation**
Tina Guanting Qiu, Founder & CEO

P

- **Photon Therapeutics Ltd.**
Mark Leddy, CEO

R

- **RECORNEA SRL**
Emiliano Lepore, Co-Founder & CEO
- **Rheon Medical SA**
Nikos Stergiopoulos, Professor & CEO

S

- **Sanoculis Ltd.**
Nir Israeli, CEO

T

- **Theialife**
Klaus Trier, Co-Founder & CSO

V

- **ViaLase Inc.**
Pete England, VP Global Marketing



Thanks to the generosity of
all of our sponsors, there is no
fee for company presentations
and virtual registration is
complimentary for everyone.

EUROPEAN FORUM

Timings are in central European summer time

07:00 – 07:40

Registration

07:40 – 07:50

Welcome

- Keith Barton
- Kuldev Singh

07:50 – 08:00

Market Overview

- Michael Giaquinto

08:00 – 08:40

Panel 1

Will MIGS Stents be Replaced by Lasers?

Panel

- Leon Au
- Antonio Boccardi
- Cameron Hudson
- Kendra Hileman
- Cathleen McCabe
- Shawn O'Neil

Co-chairs

- Keith Barton
- Ingeborg Stalmans

08:40 – 10:10

Company Presentations 1

- | | |
|--------------------------------------------------|-----------------------------------------------------------------|
| • ViaLase Inc.
Pete England | • Eye Tech Care SA
Dietrich Wolf |
| • Myra Vision Inc.
Robert Chang | • GlaucoT
Abdulkadir Oduncu |
| • Sanoculis Ltd.
Nir Israeli | • MICROT Inc.
H. Joseph Yoon, MD |
| • Liqid Medical
Daemon McClunan | • Ophthalmic Therapeutic Innovation
Tina Guanting Qiu |
| • Rheon Medical SA
Nikos Stergiopoulos | |
| • Ciliatech
Olivier Benoît | |

10:10 – 10:35

Networking Break

Sponsored by:

Alcon
SEE BRILLIANTLY

10:35 – 11:10

Panel 2

Myopia – Endpoints & Efficacy

Panel

- Annegret Dahlmann-Noor
- Yehia Hashad
- Terry Kim
- Olga Prenat
- Steve Schallhorn
- Sunil Shah

Co-chairs

- Mark Bullimore
- Ian Flitcroft

11:10 – 12:30

Company Presentations 2

- | | |
|---------------------------------------------------|-------------------------------------------------|
| • Ocumetra
James Loughman | • machine MD
Dominic Senn |
| • Occuity Ltd.
Mark Jenkins | • 2Eyes Vision
Maximo Gomez |
| • Theialife
Klaus Trier | • NovaSight Ltd.
Ran Yam |
| • Infinite Medical Ventures
Sheraz Daya | • Medevis Consulting
Kristine Morrill |
| • Lightfield Medical Inc.
Chip Berestka | |

12:30 – 13:15

Networking Lunch

13:15 – 13:45

Panel 3

Can Devices & Cell Therapies Both Succeed for Corneal Disease?

Panel

- Sajjad Ahmad
- Mor Dickman
- Nahum Ferera
- Shigeru Kinoshita
- Aimee Shimamoto

Co-chairs

- Jod Mehta
- Enrica Sarnicola

13:45 – 14:15

Panel 4

What Will be the Next Big Thing in Cataract Surgery?

Panel

- David Chang
- Kendall Donaldson
- Damien Gatinel
- Lionel Jouet
- Mark Kontos
- Franck Leveiller
- Roger Zaldivar

Co-chairs

- Arthur Cummings
- Sheraz Daya

14:15 – 15:15

Company Presentations 3

- | | |
|--------------------------------------------------|-------------------------------------------------|
| • EyeYon Medical
Nahum Ferera | • Allotex, Inc.
Michael Mrochen |
| • RECORNEA SRL
Emiliano Lepore | • Azalea Vision
Enrique Vega |
| • Epion Therapeutics Inc.
Michael Webb | • Photon Therapeutics Ltd.
Mark Leddy |
| • Intelon Optics
Dimitri Chernyak | |

15:15 – 15:50

Panel 5

European-based Biotech & Medtech Investment. Is the Appetite Growing?

Panel

- Laurent Attias
- Jan Bonel
- Frank Bulens
- Andrew Chang
- Richel Liu
- Katya Smirnyagina
- William Link

Chair

- Michael Giaquinto

15:50 – 16:20

Networking Break

16:20 – 17:10

Panel 6

Balancing Strategic Vision with Day-to-Day Operations

Panel

- Ian Bell
- Maximillian Foerst
- Warren Foust
- Shervin Korangy
- Manisha Narasimhan
- Ramin Valian

Chair

- Jim Mazzo

17:10 – 18:10

Company Presentations 4

- | | |
|---------------------------------------------|-----------------------------------------------|
| • EYE-GO A/S
Henrik Nagel | • Nordic Pharma Eye Care
Jai Parekh |
| • Max Biotech Ltd.
Sunil Shah | • EYEXORA
Theresa Heah MD, MBA |
| • COMPEX, spol. s.r.o.
Limin Wang | |
| • Oculus SA
Riad Sherif, MD | |

18:10 – 18:45

Panel 7

Will Light Adjustable Lenses Result in a Paradigm Shift?

Panel

- Gerd Auffarth
- Seba Leoni
- Magda Michna
- Michael Mrochen
- Ernesto Pelayo
- Ronald Yeoh

Co-chairs

- Vance Thompson
- Dagny Zhu

18:45 – 19:15

Panel 8

Drugs & Biologics for Front-of-the-Eye Diseases

Panel

- Ian Bell
- Michael Goldstein
- Theresa Heah
- Jai Parekh
- Riad Sherif

Chair

- Kuldev Singh

19:15 – 19:20

Concluding Comments from the Co-chairs

- Keith Barton
- Kuldev Singh

19:20 – 20:30

Reception

Sponsored by:

EYEXORA

Eyexora is a global ophthalmology company pioneering a hub-and-spoke model to accelerate innovation in eye care. By centralizing scientific, clinical, regulatory, and commercial expertise, Eyexora advances a diversified pipeline of therapies and devices through focused subsidiaries, to reduce risk, improve efficiency, and scale impact.

Founded by leaders with decades of ophthalmology experience and a track record of more than 30 successful company launches, Eyexora partners with clinician-scientists and research institutes worldwide to bring transformative eye care solutions to patients faster and smarter. For more information, visit www.eyexora.com.

SPONSORS >>BRONZE



abbvie

Allergan is now AbbVie –
Your Vision. Our Mission.

At AbbVie, we set our sights on a future where vision lasts a lifetime. With a legacy of more than 75 years in eye care, we are focused on preserving and protecting vision for patients around the world.

We treat conditions from the front to the back of the eye, including glaucoma, ocular surface disease, and retinal diseases.

Learn more at AbbVieEyeCare.com

AURION
BIOTECH

Aurion Biotech's mission is to restore vision to millions of patients with life-changing regenerative therapies. It received the prestigious Prix Galien award for best start-up in biotech. Its first drug candidate is for the treatment of corneal endothelial disease and has received regulatory and reimbursement approval in Japan. The Company has completed enrollment and dosing of its

clinical trial in the U.S. and Canada and has received Breakthrough Therapy Designation and Regenerative Medicines Advanced Therapy Designation from FDA to facilitate development of its drug candidate. Aurion Biotech is backed by Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures.

Apellis

At Apellis, we combine courageous science and compassion to develop life-changing medicines for some of the most challenging diseases patients face. Our goal is to transform treatment for a broad range of debilitating diseases by controlling a part of the immune system known as the complement cascade.

We ushered in the first new class of complement medicine in 15 years, and now have two approved medicines targeting C3, the central

protein in the cascade. These include the first-ever FDA approved therapy for geographic atrophy, a leading cause of blindness around the world.

With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across rare, retinal, and neurological diseases and are further exploring what is possible by targeting C3.

BAUSCH + LOMB


medevis[™]
EVIDENCE & ACCESS MEDICAL COMMUNICATIONS

Bausch + Lomb is a leading global eye care company celebrating over 170 years of expertise in ophthalmology. Our Surgical Division provides a comprehensive portfolio for anterior, posterior, premium and glaucoma surgery. The SeeLuma™ Fully Digital Surgical Visualization Platform is amongst our latest innovations, along with our next generation ELIOS™ technology for glaucoma surgery. The combined Stellaris Elite™ vision enhancement

system, the TENEO™ 317 M2 Excimer Laser, and the latest additions to our premium IOL portfolio, the LuxLife® and enVista Aspire™ IOLs, plus a complete retina portfolio, also feature in our range.

Meet the team on our booth during EURETINA and ESCRS congresses and learn more at our Bausch + Lomb Satellite Lunchtime Symposium on 13th September at 1pm in Auditorium 10.

A team that embodies ophthalmology in Europe, we are Medevis Consulting. It starts with a Board of Directors led by Kristine Morrill and Paul Bikard and extends through to the management team and service leaders. Medevis Consulting represents a new approach that marries

passion, experience and diligence to every project.

Our Vision: To be the partner of choice for medical device innovators in ophthalmology.



Neurotech Pharmaceuticals, Inc. is a private clinical stage biotech company focused on developing transformative therapies to slow the progression of Macular Telangiectasia (MacTel) and other chronic retinal diseases through

its core platform technology, Encapsulated Cell Therapy (ECT).

To learn more, visit www.neurotechpharmaceuticals.com.



We focus on the development and commercialization of specialty products, which include, but are not limited to, niche hospital and orphan products, to address unmet medical needs. Our expertise relies on the development and sales of our own products, but also on partner products acquired at various stages of development. Today, Nordic Pharma has a range of highly

specialized proprietary and in-licensed products in the following therapeutic areas: Rheumatology, Ophthalmology, Women's Health and Critical Care (Anaesthesia, Haematology, Oncology).

Our driving force is about innovative and efficient products to fight diseases. We strive to bring solutions to specific unmet medical needs, contributing to improved patient care.



Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis' highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01 eye drops, a topical candidate in Phase 3 for diabetic macular edema; OCS-02, a topical anti-TNF α eye drop candidate

for dry eye disease; and OCS-05, a neuroprotective candidate for acute optic neuritis. Headquartered in Switzerland with operations in the US and Iceland, Oculis' goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team and supported by leading healthcare investors.



Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across development, treatment, and outcomes. OTX-TKI (also known as AXPAXLI™), Ocular's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™

proprietary bioresorbable hydrogel-based technology. OTX-TKI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and has potential applications across other retinal diseases such as non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME).



REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV

Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.



Théa is the leading independent European pharmaceutical company specialized in the research, development, and commercialization of eye care products. Based in Clermont-Ferrand, France, this family-owned and run company comprises more than 2000 collaborators and has

expanded by opening more than 35 affiliates and offices in Europe, North Africa, North and South America, and the Middle East. Its products are available in 75 countries. In 2023, Théa's turnover reached \$1 billion.

SPONSORS >>NEW INNOVATOR



4DMT is a clinical-stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market diseases. We use our transformative vector discovery platform, termed Therapeutic Vector Evolution, to create customized and proprietary gene delivery vehicles (i.e., vectors) to deliver therapeutic payloads to specific tissue types associated with the

underlying disease via the optimal route of administration. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies.



Adverum is a clinical-stage company that aims to establish gene therapy as a new standard of care in ophthalmology with the aspiration of developing functional cures to restore vision and prevent blindness. Adverum leverages its proprietary intravitreal platform, to

develop a novel gene therapy candidate, Ixo-vec, as a one-time, in-office, injection for patients with nAMD. Adverum aspires to transform the standard of care, Preserve Sight For Life®, and create a profound societal impact around the globe.



CILIATECH is developing a groundbreaking concept called CID (Cilio-scleral Interpositioning Device): a new class of implant to address the increasing need to treat glaucoma durably and with zero adverse effects. INTERCIL® Uveal Spacer is the first implant in the industry to reduce

IOP without penetrating the anterior chamber or creating subconjunctival filtration, for open and narrow angle patients. Clinical trials show IOP is reduced by 33% at 36 months (68% patients drop free, no reoperation needed) and without ECL risk.



EyeYon Medical Ltd. is a pioneer in ophthalmologic medical devices, focusing on developing cornea-focused sight-saving solutions for more than a decade. We believe in challenging technology barriers to save the vision of millions of eyes worldwide.


EyeYon Medical is driven by a multi-disciplinary team of visionaries along with investors who see a future world with a new standard of corneal treatments, saving the sight of all those suffering from serious cornea-related conditions.



Gore Ventures accelerates innovation by investing in promising new technologies and exploring market opportunities that are new to Gore.

Purposeful Innovation: Driven by our curiosity, creativity, and collaboration, Gore develops advanced materials and new technologies that improve lives and

industries. Inspired by our founders' inventive and entrepreneurial spirit, we're constantly growing our capabilities to address society's most complex technology challenges.



Kiora Pharmaceuticals (NASDAQ:KPRX) is a clinical-stage biotechnology company developing and commercializing products for the treatment of retinal diseases. KIO-301 is being developed to treat retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with retinal degeneration.

KIO-104 is being developed to treat retinal inflammatory diseases. It is a non-steroidal, immuno-modulatory small-molecule inhibitor of dihydroorotate dehydrogenase. For more information, please visit www.kiorapharma.com, and follow us on our social media accounts including Twitter and LinkedIn.



Optigo Biotherapeutics is an innovative pre-clinical stage biotherapeutics company working to develop cutting-edge treatments to address vision loss from chronic ophthalmic diseases, many of which are currently treated by monthly or bimonthly injections of drugs into the eye(s) by a retina specialist.

We believe that by reducing the frequency at which each dose of drug is delivered, we will reduce the inconvenience, discomfort, risk and expense of existing treatments. In doing so, we hope to reduce the number of patients dropping out of their treatment cycles or having to skip doses due to inconvenient timing.



We are developing and delivering photo-crosslinked, biodegradable ocular drug delivery systems engineered to provide 6 months + sustained release for a broad range of therapeutic modalities, including Biologics, Peptides, Large and Small Molecules.

Through innovative sustained-release

therapeutics, we aim to resolve the treatment burden of frequent intravitreal injections and improve the quality of care for patients with sight-threatening diseases.

Re-Vana is working with several global pharmaceutical companies in conducting preformulation and preclinical feasibility studies.



ViaLase, Inc. is a globally-minded, venture and strategic capital-backed, clinical stage medical technology company located in Aliso Viejo, CA. ViaLase is focused on disrupting the conventional glaucoma treatment

paradigm with the introduction of a truly noninvasive image-guided femtosecond laser treatment that enhances glaucoma patient care.

For more information, visit www.ViaLase.com.

IS YOUR COMPANY INTERESTED
IN SPONSORING A FORUM?

Showcase your organisation across both
Retina & European Forums, contact:
info@ophthalmology-futures.com



EssilorLuxottica is proud to be a Silver sponsor at Ophthalmology Futures Forums 2025.



Join us at Panel 2:
Myopia - Endpoints & Efficacy



Thursday, 11 September
10:35 - 11:10 CET

Visit us at our booth in the Gallery Room
to learn more Essilor® Stellest® lenses



BVI

THE FUTURE IN FOCUS



Virtuoso®

Guess What?

The guess work stops | February 2026



bvimedical.com

BVI and all other trademarks (unless noted otherwise) are property of BVI. BVI ©2025

ZEISS at ESCRS 2025

Make data work for you.

12 – 15 September 2025, Bella Center Copenhagen



**Visit us at ESCRS 2025 in hall C,
booth C1.130.**

Advance your ophthalmic workflow
and discover all our highlights!



Seeing beyond

en-INT_32_030_01501 ©Carl Zeiss Meditec AG, 2025. All rights reserved.

The Future is EVO ICL™

Expand your offering. Elevate your outcomes.

The EVO ICL lens is an Rx only surgical implant that corrects distance vision for persons 21–45. Surgeons must be certified prior to use including training on contraindications, surgical procedure and potential benefits, risks, and complications of both the surgery and the lens. Please review the DFU available at <https://edfu.staar.com/edfu/> for complete safety and other information before performing the clinical procedure.

staar.com



STAAR™
SURGICAL



Together, We Help People See Brilliantly.

At Alcon, we aspire to lead the world in innovating life-changing vision products because when people see brilliantly, they live brilliantly.

Thanks to you, each year our products touch the lives of millions of people living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. We offer the most complete line of ophthalmic surgical devices, as well as a differentiated portfolio of contact lenses, lens care solutions, and pharmaceutical and over-the-counter eye drops. Alcon is also at the forefront of innovation, partnering with Eye Care Professionals like you to bring the gift of sight to more people around the world.

That's been our legacy for more than 75 years—and continues to guide our focus towards the brilliant future ahead.

Learn more at alcon.com

CONNECT WITH US!



@AlconEyeCare
@AlconCareers



@Alcon
@MyAlcon



@AlconLife
@AlconCareers



@SeeAlconScience



@AlconLife

